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Background: Treatment of differentiated thyroid cancer usually consists of a total thyroidectomy followed by one
or several courses of radioiodine (131I). 131I is known to have deleterious effects on radiation sensitive tissues and
irradiation to the testes has been shown after its administration. We investigated effects of such treatment on
sperm DNA in a patient with differentiated thyroid carcinoma.
Methods: The patient, a 32-year-old male with differentiated thyroid carcinoma treated by total thyroidectomy and
radioiodine therapy, performed 6 semen samples in total, 3 for sperm banking and 3 for semen exploration, that
were analysed for classic semen parameters. DNA integrity was analysed by flow cytometry: sperm DNA fragmentation
index (DFI) and high DNA stainability (HDS) were analyzed by sperm chromatin structure assay, DNA fragmentation
was analyzed by terminal deoxynucleotidyl transferase dUTP nick end labeling assay.
Results: Moderate oligozoospermia was observed as early as 3 months after a first dose of 131I and became severe at
5 months. Total sperm count was reduced up to 12 months after the second dose of 131I. Sperm DFI was increased
3.25 months after the first dose of 131I. All parameters returned to normal values 28 months after the second 131I dose.
Conclusions: Treatment with 131I induces alterations in sperm chromatin as well as in sperm parameters a short time
(3 months) after a first dose of 131I with persistence of sperm alterations until 12 months after a second dose. Sperm
banking should be recommended before treatment.
Keywords: Radioiodine therapy, SCSA, Sperm DNA fragmentation, Differentiated thyroid, Cancer, Semen characteristicsRésumé
Contexte: Le traitement du cancer différencié de la thyroïde consiste en général en une thyroïdectomie totale suivie
d’un traitement par l’iode radioactif (131I). L’131I est connu pour ses effets délétères sur les tissus sensibles aux radiations
et il a également été démontré une irradiation des testicules après administration d’iode radioactif. Nous avons donc
cherché à savoir quels étaient les effets du traitement par l’iode radioactif sur l’ADN des spermatozoïdes.
Méthodes: Le patient est un homme de 32 ans présentant un cancer différencié de la thyroïde traité par thyroïdectomie
totale puis traitement par iodothérapie. Il a réalisé 6 prélèvements de sperme, 3 pour de l’autoconservation et 3 pour le
suivi après traitement, dont les caractéristiques spermatiques ont été étudiées suivant les méthodes classiques. L’analyse
de l’intégrité de la chromatine a été réalisée par cytométrie en flux : l’index de fragmentation de l’ADN (DFI) et la haute
colorabilité de l’ADN (HDS) ont été analysés par le sperm chromatin structure assay (SCSA), la fragmentation de l’ADN a
été évaluée par la technique de terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL).
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Résultats: Une oligozoospermie modérée a été observée dès 3 mois après une première dose de 131I, et est devenue
sévère à 5 mois. La numération des spermatozoïdes est restée réduite jusqu’à 12 mois après la seconde dose de 131I.
Le DFI est élevé 3.25 mois après la première dose de 131I. Tous les paramètres ont retrouvé des valeurs normales
28 mois après la seconde dose d’131I.
Conclusion: Le traitement par 131I induit des altérations de la chromatine du spermatozoïde en plus de celles
des caractéristiques spermatiques une courte période (3mois) après une première dose de 131I, avec persistance
de ces altérations spermatiques jusqu’à 12 mois après une seconde dose. L’autoconservation devrait être
recommandée avant un tel traitement.
Mots clé: Traitement par iode radioactif, SCSA, fragmentation de l’ADN du spermatozoïde, cancer différencié de
la thyroïde, paramètres spermatiques.Background
Differentiated thyroid cancer (DTC) is the most com-
mon endocrine malignancy. It affects any age group and
sex, and its incidence has been increasing for the last
20 years [1, 2]. Treatment of DTC includes thyroidec-
tomy, followed by nuclear medicine therapy with radio-
iodine 131I for eradication of persistent disease and
ablation of residual thyroid remnant, to facilitate post-
treatment radiological and clinical follow-up of the pa-
tient [3]. 131I treatment can damage radiation-sensitive
tissues, and it has been shown that some radiation is de-
livered to the testes after administration of radioiodine
[4]. Some studies have reported impairment in sper-
matogenic functions such as elevated serum FSH levels,
reduced sperm count resulting in some cases in oligo-
zoospermia [5–8]. These effects were usually not per-
manent and were reversed within 18 months, although
permanent damage has been reported in patients receiv-
ing repeated or high cumulative doses [9]. Radiations are
known to induce double strand breaks in DNA, and it
has been shown that treatment with 131I induces a rise
in γH2AX and 53BP1 DNA repair foci in blood cells
[10]. There are no reports on potential effects on sperm-
atozoa DNA, although it has been shown that higher
levels of DNA strand breaks are associated with infertil-
ity and miscarriages [11].
We report the case of a 32-year-old man in whom sev-
eral sperm analyses were carried out after treatment with
131I for differentiated thyroid carcinoma. Each sample was
analyzed for classic semen parameters. For the first time,
we report the effects of radioiodine therapy on spermato-
zoa chromatin and DNA, evaluated by sperm chromatin
structure assay (SCSA) and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay.
Subject
A 32-year-old man presented with thyroid carcinoma
classified pT3N1R1. One month after a total thyroidec-
tomy, he was treated with 150 mCi of radioiodine (131I).
A second dose of 150 mCi 131I was administered7 months later. The patient was referred to the CECOS
for sperm banking 3 months after the first dose of 131I
and before the scheduled second dose. He was seen
twice during the two months after his first sperm bank-
ing, and three times after his second dose of 131I, at 12,
28 and 57 months. The patient gave a total of 6 samples,
3 for sperm banking and 3 for exploration (Fig. 1). The
present study was carried out in accordance with the Dec-
laration of Helsinski and the patient gave his informed
consent for the study. All samples and exposure data were
provided by the GERMETHEQUE Biobank (France).
Semen analysis
Sperm samples were collected by masturbation after 3–6
days of sexual abstinence, except for sample 1 where ab-
stinence was 30 days. Semen was allowed to liquefy 30 min
at 37 °C before parameters were analyzed. Conventional
semen analysis was performed according to WHO criteria
[12]. Sperm count (SC), total sperm count (TSC), motility
a + b (rapidly progressive—grade a, slowly progressive—
grade b) (MOT) were assessed. Sperm vitality (VIT) was
determined by eosin-nigrosin. Semen samples were cryo-
preserved within 1 h of collection according to the stand-
ard procedures used for sperm banking in our laboratory
until later processing for testing DNA integrity [13].
Spermatozoa fixation
Prior to SCSA and TUNEL, cells were fixed with 1 %
paraformaldehyde. Briefly, spermatozoa were collected
by thawing straws of the different samples at room
temperature. Cryoprotector medium was washed by add-
ing 5 ml of PBS medium, drop by drop to 1 ml then more
rapidly for the remaining 4 ml, and centrifuging at 630 g
for 10 min. Cells we resuspended in 1 ml of PBS and 4 ml
of 1 % paraformaldehyde and incubated 30 min at room
temperature. Samples were then centrifuged 10 min at
1500 g, the supernatant discarded and cells resuspended
in the appropriate volume of PBS. Samples were kept at
4 °C until processed. A minimum of 13 × 106 spermatozoa


















0 3.25 5.25 7 19                                     35                                                        64
0 12 28                                                                       57 Time after 2nd dose 
131I (months)
-1          3
Time after 1st dose 
131I (months)5
Fig. 1 Semen exploration according to time after surgery and 131I treatments The upper line represents time in months after the first 131I treatment,
the lower line time in months after the second 131I treatment. Numbers in circles represent ejaculates, ex: 1 = 1st ejaculate. 150 mCi 131I represents
the two treatments by 131I. Total thyroidectomy and Jugular-carotid lymph node dissection represent the two surgeries the patient underwent
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SCSA test was possible on 4 × 106 spermatozoa.
Sperm chromatin structure assay
Sperm DFI and high DNA stainability (HDS) were mea-
sured according to conventional sperm chromatin struc-
ture assay (SCSA) as described by Evenson and Jost [14]
and routinely used in our laboratory. In brief, 2 × 106
cells were centrifuged at 1500 g for 10 min and trans-
ferred into a cytometer tube. Each sample was run in
duplicate. Cells were resuspended by vortexing, then
0.4 ml of acid detergent (pH 1.2) was added. The tube
was gently shaken for 30 s before adding 1.2 ml of acrid-
ine orange and incubated 3 min on ice. 5,000 cells were
acquired by fluorescence-activated cell sorting (FACS)
on a FC500 cytometer (Beckman Coulter Inc., Fullerton,
CA, USA). The DNA fragmentation index (DFI) was de-
fined as the ratio of denatured DNA (red fluorescence)
to total DNA (red + green fluorescence). High DNA
stainability (HDS) was calculated as the percentage of
cells presenting a high level of red fluorescence.
DNA strand break measurement
DNA strand breaks were measured using the terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay. A detailed protocol for the TUNEL
assay of human sperm has previously been described
[15]. Terminal deoxynucleotidyl transferase (TdT) en-
zyme, reaction buffer, CoCl2 and dUTP biotin were pur-
chased from Roche Diagnostics (Mannheim, Germany).
Streptavidin FITC was purchased from Tebu-Bio (Le
Perray-en-Yvelines, France), and propidium iodide fromSigma Aldrich (St Louis, MO, USA). For each specimen,
a negative sample without enzyme and two positive sam-
ples with enzyme were tested. The percentage of cells
presenting DNA strand breaks was calculated by sub-
tracting the percentage of fluorescence in the control
(no TdT enzyme) from the mean percentage of fluores-
cence of the two TdT-positive samples. 10,000 cells were
acquired by FACS on a FC500 cytometer (Beckman
Coulter Inc., Fullerton, CA, USA).Results
Treatment by 131I induces perturbations in semen
parameters
The patient was seen 6 times for sperm banking and
evaluation of semen parameters. The first 3 samples
were obtained 3.25, 5 and 5.25 months after the first
dose of 131I. The other samples were obtained 12, 28
and 57 months after the second dose (Fig. 1). Results of
analysis of semen parameters are shown in Table 1.
Three months and 1 week after the first dose of radioio-
dine, moderate oligozoospermia (SC and TSC) was ob-
served, and became severe at 5 and 5.25 months after
the first treatment. The percentage of progressive motile
spermatozoa was lower than normal values after the first
dose of 131I, 3.25 (20 %) and 5.25 months post-treatment
(30 %).
TSC was lower than normal values 12 months after the
second dose of radioiodine (32 × 106 spermatozoa). At
twenty-eight months, SC, TSC, MOT and VIT returned to
normal values. By 57 months post-treatment, all semen
parameters were normal.
Table 1 Sperm characteristics and DNA fragmentation values evaluated by TUNEL assay after 131I treatments
Time after 1st dose (months) Time after 2nd dose (months)
3.25 5 5.25 12 28 57
Sexual abstinence (days) 30 4 4 6 3 5
Volume (ml) 1.3 1.6 1.45 1.6 1.55 2.1
Sperm count (× 106/ml) 18 4 3.5 20 100 183
Total sperm count (× 106) 23.4 6.4 5.1 32 155 384.3
Motility a + b (%) 20 35 30 35 50 40
Viability (%) 51 45 67 62 83 65
TUNEL value (%) 10.5 ND ND 3.4 5.1 3.35
Normal values (WHO laboratory manual for the examination and processing of human semen, 5th edition, 2010): volume > 1.5 ml, sperm count > 15 × 106/ml,
total sperm count > 39 × 106/ejaculate, motility > 32 %, viability > 58 %. ND: not determined
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The DNA fragmentation index (DFI) measured by SCSA
was under the threshold value of 20 %, defined in our la-
boratory [16] as the 90th percentiles of SCSA values of
51 fertile men, for all samples except for specimen 1 col-
lected 3.25 months after the first dose of 131I, where DFI
was highest (24.5 %) (Fig. 2).
Values decreased to 12.9 % and 16.5 % at 5 and
5.25 months after the first dose. Twelve months after
the second dose of 131I the value remained stable at
16.1 %. The lowest values were found at 28 and
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Fig. 2 Variation of sperm DNA fragmentation after 131I treatment DNA Frag
measured on 2 x 106 cells by the SCSA assay. Each dot represents the me
represents surgeries, represents 131I treatments. The Y axis representsand 11.8 %, respectively). HDS values remained con-
stant during the whole study period (around 4 %),
under the threshold value of 7.5 %, with a slight eleva-
tion to 6.45 % at 5.25 months after the first dose
(Fig. 2).
The percentage of cells with fragmented DNA assessed
by TUNEL was in the normal range during the study,
i.e. <16.5 % [16] (Table 1), although the highest value
was found 3.25 months after the first dose of 131I
(10.5 %). The technique could not be performed in sam-
ples at 5 and 5.25 months after the first dose of radioio-
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A few studies have reported the effects of radioiodine ther-
apy for thyroid cancer on sperm characteristics [5–7, 17–19]
but none has analyzed the consequences of such treat-
ment on sperm DNA. For the first time, we report a tran-
sient sperm DNA fragmentation increase 3.25 months
after administration of a single dose of 150 mCi of radioio-
dine. Our case report shows major alterations of sperm
characteristics 3.25, 5 and 5.25 months after a single dose
of 150 mCi radioiodine, consisting of moderate to severe
oligozoospermia, moderate to severe asthenospermia,
necrospermia and hypospermia. It is noteworthy that very
severe effects on sperm production were also noted 3–6
months after the end of treatment of testicular cancer by
adjuvant radiotherapy, although the irradiation mode was
totally different [16]. These observed alterations of sperm
characteristics are consistent with the findings of severalTable 2 Published effects of one or several doses of 131I on sperm p
Authors Number of
patients
Dose of 131I (mCi) Time after 1
(months)
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Rosario et al., 2006 [7] 52 100–150
6
12
18studies that show a decrease in total sperm count and nor-
mokinetic sperm in patients treated with 30 mCi to more
than 600 mCi of 131I, as summarized in Table 2. Moreover,
an increase in FSH as early as 3 months after doses of
150–700 mCi of 131I has been reported by Wichers et al.
[6], with a maximum value 6 months after therapy and re-
covery of the pre-treatment mean value by 18 months. To
date, no study has reported results concerning potential
damage to spermatozoa chromatin and DNA although it
is known that treatment with 131I induces radiation to the
testes [4], mainly through contamination of blood and
bladder urine. Radiation is known to induce alterations in
cell DNA, so it makes sense to assume that radiation is-
sued from treatment by 131I can affect spermatozoa DNA.
Our results show that DFI and DNA fragmentation values
were highest 3.25 months after the first dose of 131I, and
then decreased at a distance from the second dose. Thesearameters and serum FSH levels
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4: 11 × 106 ≤ SC≤ 32 × 106
12.3 ± 7.5
9 men performed sperm analysis:
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↑ FSH after 2nd dose back
to normal by 12 months
24.2 ± 3.2 oligozoospermia in 66% patients
with elevated FSH 18 months
after treatment9.5 ± 1.9
5.9 ± 1.9
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testifying that radioiodine affects not only classic sperm
parameters but also the genetic material of spermatozoa.
We assume these consequences may be due to the radi-
ation, although we cannot rule out a possible effect of the
tumor context itself. Unfortunately, we have no sperm
sample obtained before radiation, so we cannot be certain
that this patient’s sperm DNA parameters were normal.
But we do know that this patient fathered two children
without difficulty (Time to pregnancy, 3 months), and his
excellent sperm parameters at a distance from the end of
therapy (28 and 57 months) lead us to think that all pa-
rameters were normal prior to his treatment. One of the
limits of our study is that we were not able to investigate
the possible epigenetic effects of 131I radiation. Potential
modifications might be expected, as it has recently been
shown that rats exposed to 20 Gy of X-ray to the brain,
and whose body was protected by a shield, present a de-
crease in DNA methylation in testicular tissue as well as
in mature sperm cells [20]. Another study on health
workers occupationally exposed to ionizing radiations
shows an increase in DNA methylation in the spermato-
zoa of these men [21]. Unfortunately we lack the material
to answer such a question but it would be of interest to in-
vestigate this aspect in future studies.
Conclusions
For the first time, our study shows alterations in sperm
chromatin and DNA as well as in sperm parameters a short
time (3 months) after a first dose of 131I. Sperm characteris-
tics were still altered 12 months after a second dose.
Although these results need to be confirmed in more sub-
jects, they should encourage us to do a prospective study to
explore genetic and epigenetic modifications on a group of
patients who are to receive 131I treatment. While awaiting
the results of such a study, recommendation for sperm
banking before starting radioiodine treatment should be the
rule for young patients of reproductive age.
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